title: [Immunosuppression in inflammatory bowel disease:  When, how and how long?].
abstract: Immunosuppressive treatment is an important tool in the therapy of patients with inflammatory bowel disease. Treatment goal is a long lasting remission. Candidates for immunosuppressive treatment are patients with steroid-refractory active disease, steroid-dependency, chronic active disease or frequent relapses. Conventional immunosuppressives (azathioprine/6-mercaptopurine, methotrexate, the calcineurin inhibitors cyclosporine A and tacrolimus), and anti-TNF antibodies (infliximab, adalimumab) are available. Current guidelines set the frame for the rational use of these drugs.
authors.affiliation: Medizinische Klinik II, Klinikum St. Marien Amberg. gross.volker@klinikum-amberg.de
authors.forename: V
authors.initials: V
authors.lastname: Gross
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D057915:Drug Substitution; D005500:Follow-Up Studies; D019983:Guideline Adherence; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D008134:Long-Term Care; D012008:Recurrence; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069285:Infliximab; D000068879:Adalimumab